These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 23253272)

  • 1. New oral anticoagulants for stroke prevention in atrial fibrillation: impact of gender, heart failure, diabetes mellitus and paroxysmal atrial fibrillation.
    Ahmad Y; Lip GY; Apostolakis S
    Expert Rev Cardiovasc Ther; 2012 Dec; 10(12):1471-80. PubMed ID: 23253272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of new drugs for management of atrial fibrillation.
    Hollands JM; Gowan M; Riney JN; Deal EN; Kates AM
    Ann Pharmacother; 2012 Dec; 46(12):1656-70. PubMed ID: 23249869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis.
    Agarwal S; Hachamovitch R; Menon V
    Arch Intern Med; 2012 Apr; 172(8):623-31; discussion 631-3. PubMed ID: 22450212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternatives to chronic warfarin therapy for the prevention of stroke in patients with atrial fibrillation.
    Lam YY; Ma TK; Yan BP
    Int J Cardiol; 2011 Jul; 150(1):4-11. PubMed ID: 21112648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
    Patel MR; Hellkamp AS; Lokhnygina Y; Piccini JP; Zhang Z; Mohanty S; Singer DE; Hacke W; Breithardt G; Halperin JL; Hankey GJ; Becker RC; Nessel CC; Berkowitz SD; Califf RM; Fox KA; Mahaffey KW
    J Am Coll Cardiol; 2013 Feb; 61(6):651-8. PubMed ID: 23391196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gender differences in stroke risk of atrial fibrillation patients on oral anticoagulant treatment.
    Poli D; Antonucci E; Grifoni E; Abbate R; Gensini GF; Prisco D
    Thromb Haemost; 2009 May; 101(5):938-42. PubMed ID: 19404548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing the guidelines: anticoagulation therapy to optimize stroke prevention in patients with atrial fibrillation.
    Rockson SG; Albers GW
    J Am Coll Cardiol; 2004 Mar; 43(6):929-35. PubMed ID: 15028346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New oral anticoagulants in elderly patients with atrial fibrillation.
    Deedwania PC
    Am J Med; 2013 Apr; 126(4):289-96. PubMed ID: 23369212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stroke prevention in atrial fibrillation: do we still need warfarin?
    Diener HC; Weber R; Lip GY; Hohnloser SH
    Curr Opin Neurol; 2012 Feb; 25(1):27-35. PubMed ID: 22143201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stroke event rates in anticoagulated patients with paroxysmal atrial fibrillation.
    Lip GY; Frison L; Grind M;
    J Intern Med; 2008 Jul; 264(1):50-61. PubMed ID: 18266660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The need for new oral anticoagulants in clinical practice.
    Hylek EM
    J Cardiovasc Med (Hagerstown); 2009 Aug; 10(8):605-9. PubMed ID: 19571764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implications of the CHA(2)DS(2)-VASc and HAS-BLED Scores for thromboprophylaxis in atrial fibrillation.
    Lip GY
    Am J Med; 2011 Feb; 124(2):111-4. PubMed ID: 20887966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Antithrombotic therapy for stroke prevention in patients with atrial fibrillation].
    Tomita F; Kohya T; Kitabatake A
    Nihon Rinsho; 2000 Jun; 58(6):1326-34. PubMed ID: 10879060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation. Pooled analysis from the SPORTIF III and V studies.
    Diener HC;
    Cerebrovasc Dis; 2006; 21(4):279-93. PubMed ID: 16449807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticoagulants in patients with atrial fibrillation and end-stage renal disease.
    Brimble KS; Ingram AJ; Eikelboom JW; Hart RG
    Postgrad Med; 2012 Nov; 124(6):17-25. PubMed ID: 23322135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of warfarin use in atrial fibrillation patients in the inpatient setting.
    Agarwal S; Bennett D; Smith DJ
    Am J Cardiovasc Drugs; 2010; 10(1):37-48. PubMed ID: 20104933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apixaban for stroke prevention in atrial fibrillation: a review of the clinical trial evidence.
    Yates SW
    Hosp Pract (1995); 2011 Oct; 39(4):7-16. PubMed ID: 22056819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atrial fibrillation and stroke prevention.
    Kakar P; Lip GY
    Expert Rev Neurother; 2006 Oct; 6(10):1523-30. PubMed ID: 17078791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA).
    Pengo V; Crippa L; Falanga A; Finazzi G; Marongiu F; Palareti G; Poli D; Testa S; Tiraferri E; Tosetto A; Tripodi A; Manotti C;
    Thromb Haemost; 2011 Nov; 106(5):868-76. PubMed ID: 21946939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.